Quick Answer
Amphastar Pharmaceuticals, Inc. reported Net Income of $98.09 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $98.09M | -38.5% |
| 2024 | $159.52M | +16.0% |
| 2023 | $137.54M | +50.5% |
| 2022 | $91.39M | +47.1% |
| 2021 | $62.12M | +4327.4% |
| 2020 | $1.40M | -97.1% |
| 2019 | $48.94M | +952.9% |
| 2018 | -$5.74M | -257.3% |
| 2017 | $3.65M | -62.9% |
| 2016 | $9.82M | +452.4% |
| 2015 | -$2.79M | +74.0% |
| 2014 | -$10.70M | -190.2% |
| 2013 | $11.86M | -34.4% |
| 2012 | $18.09M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.35M | -57.1% | -44.1% |
| June 30, 2025 | $31.03M | -18.2% | +22.7% |
| March 31, 2025 | $25.29M | -41.4% | -37.5% |
| September 30, 2024 | $40.43M | -17.9% | +6.5% |
| June 30, 2024 | $37.95M | +45.3% | -12.1% |
| March 31, 2024 | $43.18M | +65.9% | -12.3% |
| September 30, 2023 | $49.22M | +210.1% | +88.4% |
| June 30, 2023 | $26.12M | +50.6% | +0.4% |
- Amphastar Pharmaceuticals, Inc. showed a decrease of -38.5% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Amphastar Pharmaceuticals, Inc.’s net income has grown by 442.1% (from $18.09 million to $98.09 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: